September 20, 2019
Cost-effectiveness of baseline genotyping upon diagnosis of HIV
The use of INSTI-based first-line regimens in the US, baseline genotyping no longer offers clinical benefit and is not cost-effective
Journal Watch
September 20, 2019
Effectiveness of intravenous fluids for Ebolavirus disease
After adjustment for patient and treatment-specific time varying factors, there were no significant differences in survival among patients with Ebolavirus disease treated with IV fluids compared to those not treated with fluids.
September 19, 2019
Safety and efficacy of bictegravir, emtricitabine and tenofovir alafenamide for HIV – second study
Bictegravir, emtricitabine and tenofovir alafenamide is a safe, well-tolerated and durable treatment for people infected with chronic HIV.
September 19, 2019
Safety and efficacy of bictegravir, emtricitabine and tenofovir alafenamide for the treatment of HIV
The combination of bictegravir, emtricitabine and tenofovir alafenamide is a safe, well-tolerated and durable alternative for the treatment of HIV
September 18, 2019
HIV transmission risk between serodiscordant gay couples when HIV viral load is suppressed
There appears to be a similar zero HIV transmission risk for gay men to that previously found for heterosexual couples. These findings support the message of the U=U (undetectable equals untransmittable) campaign, and demonstrates the benefits of early testing and treatment.
September 18, 2019
Use of dried blood spots for viral load monitoring in antiretroviral-treated HIV-infected patients in Zambia
The partial use of dried blood spots will help achieve improved viral load monitoring access for antiretroviral-treated HIV-infected patients in Zambia at the lowest cost per correct result.
Our Partners
Upcoming Events
Join the discussion
Login or register to start contributing to our message boards
Disclaimer
The information contained in this website is provided ‘as is’ without warranty of any kind. The entire risk as to the results and the performance of the information is assumed by the user, and in no event shall The UK Clinical Virology Network be liable for any consequential, incidental or direct damages suffered in the course of using the information on this website. Use of the information contained on this website are governed by their respective license agreements and may contain restrictions on use.
The UK Clinical Virology Network does not endorse or recommend any commercial products, processes, or services.
In the news
June 24, 2019
CVN meeting 2020 – expressions of interest
May 09, 2019
Post: Specialist BMS in Virology (Band 6) – Southampton
January 17, 2019
Pre-existing mutations make hepatitis C virus genotype 4r more difficult to treat
January 08, 2019
Consultant in Virology and Infectious Diseases – King’s College Hospital
November 14, 2018
SMI V 53: Screening and monitoring for hepatitis E infection
November 12, 2018